Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: A report from the Children’s Oncology Group-Reference-Cited by-同舟云学术

Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: A report from the Children’s Oncology Group

Published:2013-07 Issue:10 Volume:49 Page:2384-2391
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Goldsby Robert E.,Fan Timothy M.,Villaluna Doojduen,Wagner Lars M.,Isakoff Michael S.,Meyer James,Lor Randall R.,Lee Sharon,Kim Grace,Bernstein Mark,Gorlick Richard,Krailo Mark,Marina Neyssa

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference41 articles.

1. A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI);Voute;Ann Oncol,1999

2. A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis;Patel;Cancer,2004

3. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols;Kager;J Clin Oncol,2003

4. Osteogenic sarcoma with clinically detectable metastasis at initial presentation;Meyers;J Clin Oncol,1993

5. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children’s Research Hospital OS-91 trial;Meyer;J Clin Oncol,2001

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metallocompounds as anticancer agents against osteosarcoma;Drug Discovery Today;2024-09

2. An evaluation of the combination effect of zoledronate and chemotherapeutic agents in canine osteosarcoma cells;Frontiers in Veterinary Science;2024-02-13

3. Progress in Metastasis and Treatment of Osteosarcoma;International Journal of Biology and Life Sciences;2023-05-20

4. Spontaneous medication-related osteonecrosis of the jaws in a 23-year-Old;Oral and Maxillofacial Surgery Cases;2023-03

5. Medication-Related Osteonecrosis of the Jaws (MRONJ) in Children and Young Patients—A Systematic Review;Journal of Clinical Medicine;2023-02-10